The Art and Science of Managing the New Melanoma Landscape - Case Based Discussion

1. Utilize emerging data about the potential indications, safety, and efficacy of adjuvant therapy for patients with high-risk clinically localized melanoma
2. Describe the rationale for neoadjuvant therapy for patients with stage III melanoma and the prognostic significance of the pathological response to treatment
3. Summarize treatment options for patients with stage IV melanoma, and the patients that are not served well by currently available treatments
4. Describe the differences in the presentation and diagnosis of the various nonmelanoma cutaneous cancers (BCC, SCC, Merkel Cell Carcinomas).
5. Examine the indications for immunotherapy in nonmelanoma skin cancers, and the subtleties in response patterns and outcomes.

A FREE Virtual Live Streaming Course

The conference will run from 8:00 am – 2:30 pm on Saturday, February 12, 2022.

The registration deadline is Friday, February 4, 2022. 

Once you complete your registration, a receipt can be found in the MyCE area of your PEP@MD Anderson account. 

The Zoom information and all other necessary links will be emailed out the week of the conference. 

Telephone registrations are not accepted.

When registering online a receipt (confirmation letter) will be automatically emailed to you.

Cancellation Policy

The Department of Continuing Professional Education (CPE), reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary.  Each registrant will be notified by e-mail. In case of activity cancellation, the liability of the Department of Continuing Professional Education (CPE), is limited to the registration fee. Continuing Professional Education (CPE), will refund the full registration fee. 

The Department of Continuing Professional Education (CPE), reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. 

For additional information, contact Continuing Professional Education (CPE), at 713-792-2223 or toll free at 866-849-5866 or via e-mail: [email protected]. 

Special Assistance

Contact the Department of Continuing Professional Education (CPE), at 713-792-2223 or toll free at 866-849-5866 if you have any ADA accommodation needs

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Vinodh A. Kumar, MD
Professor
UT MD Anderson Cancer Center

CE Reviewer

Nothing to disclose

Rodabe N. Amaria, MD
Associate Professor, Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center

Co-Director, Faculty

Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Lovance|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Lovance|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nektar

Michael A. Davies, MD
Professor
MD Anderson Cancer Center

Co-Director, Faculty

Paid consultant-Roche|Paid consultant-Pfizer Inc.|Paid consultant-Novartis Pharmaceuticals Corporation|Paid consultant-Bristol-Myers Squibb Company|Paid consultant-ABM Therapeutics|Paid consultant-Apexigen|Grant or research support-Pfizer Inc.

Devarati Mitra, MD
Assistant Professor
MD Anderson Cancer Center

Co-Director, Faculty

Nothing to disclose

Kelly Nelson, MD
The University of Texas MD Anderson Cancer Center

Co-Director, Faculty

Nothing to disclose

Merrick I. Ross, MD, FACS
Professor of Surgery
UT MD Anderson Cancer Center

Co-Director, Faculty

Nothing to disclose

Carlos A Torres Cabala, MD
Professor
The University of Texas MD Anderson Cancer Center

Co-Director, Faculty

Nothing to disclose

Michael K Wong, MD, PhD, FRCPC
Physician in Chief
Roswell Park Comprehensive Cancer Center

Co-Director, Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron Pharmaceuticals, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-EMD Serono Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ExiCure|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Castle Biosciences, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Adagene

Phyu Aung, MD
Professor
MD Anderson Cancer Center

Faculty

Nothing to disclose

Ahsan Farooqi, MD
Assistant Professor
UT MD Anderson Cancer Center

Faculty

Nothing to disclose

Jeffrey E. Gershenwald, MD
Professor
The University of Texas MD Anderson Cancer Center

Faculty

Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended)

Ryan P. Goepfert, MD
MD Anderson

Faculty

Nothing to disclose

Neil D. Gross, MD
Professor
MD Anderson Cancer Center

Faculty

Grant or research support-Regeneron Pharmaceuticals, Inc.|Paid consultant-Genzyme Corporation|Membership on Advisory Committees or Review Panels, Board Membership, etc.-PDS Biotechnology|Paid consultant-Intuitive Surgical, Inc.|Paid consultant-Dragonfly Therapeutics

Emily Z. Keung, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center

Faculty

Nothing to disclose

Jennifer L. McQuade, MD
JMQ Oncology Advisors

Faculty

Honoraria-Merck Sharp & Dohme Corp. (any division)

Michael Migden, MD
Professor
UT MD Anderson Cancer Center

Faculty

Advisor-Sanofi Genzyme|Advisor-Regeneron Pharmaceuticals, Inc.|Advisor-Replimune|Advisor-Sun pharmaceuticals

Priyadharsini Nagarajan, MD
Associate Professor, Pathology, Anatomical
University of Texas MD Anderson Cancer Center

Faculty

Nothing to disclose

Hussein A. Tawbi, MD
Professor, Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center

Faculty

Consulting Fee-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-Novartis Pharmaceuticals Corporation|Consulting Fee-Genentech, Inc.|Consulting Fee-Pfizer Inc.|Consulting Fee-Iovance|Consulting Fee-Eisai, Inc.|Consulting Fee-Karyopharm Therapeutics|Consulting Fee-Boxer Capital|Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Genentech, Inc.|Grant or research support-GlaxoSmithKline

Allison Baring, BA
Program Manager
The University of Texas MD Anderson Cancer Center

Planning Committee Member

Nothing to disclose

Saturday, February 12, 2022